InfoAnda - Workers Squeezed As Employers Pass Along High Costs Of Specialty Drugs

Pakistanis angry over detentions in Times Sq. case
Monday, May 24, 2010
ISLAMABAD – Relatives of three men detained by Pakistan for alleged links to the suspect in the attempted Times Square bombing say the men are innocent.
They

Taiwan denies boycotting Australian film festival
Thursday, August 6, 2009

AFP - Thursday, August 6TAIPEI (AFP) - - Taiwan's Beijing-friendly government on Wednesday denied boycotting an Australian film festival amid a row over the e

Merkel's support dips, regional ally resigns International
Thursday, September 3, 2009

By Sarah Marsh and Noah Barkin

BERLIN (Reuters) - Chancellor Angela Merkel suffered a double blow on Thursday as a senior party ally in east German

Minister seeks closure of anti-Berlusconi websites
Wednesday, December 16, 2009
ROME (AFP) - – The Italian government moved Tuesday to close down Internet sites encouraging further violence against Prime Minister Silvio Berlusconi, who

Asian markets mixed after Wall Street rally
Wednesday, March 18, 2009

By ELAINE KURTENBACH,AP Business Writer AP - Wednesday, March 18SHANGHAI - Asia's stock market rally seemed to be running out of steam Wednesday, despite an

Kings of Leon abandon U.S. concert due to pigeon poop | | 26 July 2010
T-Mobile USA kicks off corporate Wi-Fi push | Technology | | 5 October 2009
Ahmadinejad threatens to 'cut' attackers' hands | 22 September 2009

Sprint, cable operators in Clearwire talks: sources | | 20 August 2011

Advertisement Workers Squeezed As Employers Pass Along High Costs Of Specialty Drugs Source: (KaiserHealth) Reporter: KaiserHealth Staff Location: Washington, DC, United States Published: August 22, 2011 08:03 pm EDT Topics: Health, Patient, Labor, Economy, Business And Finance, Financial And Business Service, Insurance For Judy Ariba, one of the most harrowing moments in her battle against a rare form of leukemia occurred after she had already endured a long hospital stay and grueling chemotherapy: Her bill for a prescription cancer drug jumped from $10 to $1,700 a month. After Judy Ariba’s former employer switched to a new health plan that required her to pay a percentage of her prescription cancer drug rather than a co-pay, her bill jumped from $10 to $1,700 a month. (Photo by Shane Bevel, for USA Today) "No one has $1,700 a month," said Ariba, 63, of Siloam Springs, Ark. "I sat here and cried for a while, thinking 'I've gone through all this, and now I will get sicker and die.'" Ariba’s drug costs soared because her former employer, a Florida-based construction firm, switched to a new health plan that required her to shoulder 25 percent of the $6,800 monthly cost of Tretinoin, a drug for acute promyelocytic leukemia. Ariba was caught in one of the most difficult issues facing employers and consumers who pay for health insurance: How to deal with an increasing number of expensive "specialty" drugs for conditions ranging from cancer to multiple sclerosis. The drugs offer hope for curing or managing diseases, but carry hefty price tags. Employers’ spending on specialty drugs, for example, is rising by double digits each year. To try to control spending, some employers are requiring patients to pay a percentage of the cost of specialty drugs — from 25 percent to 33 percent or more — rather than a flat dollar co-payment. Surveys show that 13 percent to 17 percent of employers have added a specialty category to their drug benefits, and more are likely to adopt them, given that more than 600 specialty drugs are in development. The idea of paying differing amounts for types of prescription drugs is not new. Employers and insurers have long used "tiers" to set the amounts patients pay for generic drugs, brand-name products and "non-preferred" brand-name drugs. Such policies have helped increase the use of generic drugs and steered patients to the branded products on which insurers receive the largest discounts. But specialty tiers didn’t catch on until the Medicare prescription drug program, which began in 2006, allowed them for certain costly drugs. Now, about 85 percent of Medicare drug plans include such tiers, according to consulting firm Avalere Health in Washington. If more employers embrace specialty tiers, with their higher patient costs, "that would be a disaster," says Amy Melnick of the Arthritis Foundation. Differing views The practice of using specialty tiers divides benefit consulting firms. While some say that requiring higher patient payments is a useful tool to control drug spending, others warn their employer clients that the approach could discourage workers from taking needed medications. If patients skimp on expensive drugs, "it can render the drug ineffective," says Lisa Zeitel, a senior vice president with Aon Hewitt, a benefits consulting firm. Then the employer has "thrown a lot of money down the drain," she says. The controversy has prompted lawmakers in about a dozen states to propose barring or restricting specialty drug tiers. The issue is getting attention at the national level, too: Federal officials will have to decide whether to allow such specialty pricing in the "essential benefit packages" that all insurance sold through new online marketplaces called exchanges will be required to offer starting in 2014. Depending on the insurer, dozens to hundreds of medications are considered specialty drugs — either because of the way they're made, their costs or both. Some of the drugs are liquid and are injected, while others are in pill form. Many cost more than $2,000 a month. Often called "biologics," specialty drugs are used by only a small percentage of patients. But they represent the fastest-growing category of spending by employers on prescription drugs, according to several recent studies, because of their high cost. Some insurance plans set an upper annual cap on how much patients have to pay out of pocket for such medications, while others leave the policyholder exposed to unlimited costs. Already, five drugs in this category — Humira, Enbrel and Remicade for forms of arthritis and Avastin and Rituxan for cancer — are among the top 10 selling drugs worldwide by revenue, according to data from Medco, a company that runs pharmacy benefit programs for employers and insurers. Worldwide, the five drugs accounted for $29 billion in sales in 2009. The drugs are helping to replace revenue expected to be lost as more traditional drugs lose their patent protection and go generic, which causes prices to fall dramatically. "These are high-margin, long-term (use) drugs," says David Dross, a consultant with benefits firm Mercer. "That's the jackpot for drugmakers." Robert Zirkelbach, spokesman for America’s Health Insurance Plans, the industry’s lobbying group, says the specialty charges are one way insurers try to keep premiums down, but blamed the real problem on drugmakers: "Why do these specialty drugs cost several hundred thousand dollars for a few years’ treatment? That needs to be part of this discussion." Drugmakers counter that such products can cost millions to produce, justifying the cost to insurers. But they don’t like specialty tiers because they’re worried tiers discourage use of the drugs. "The existence of the specialty tier in America’s health care system, in both the public and private sectors, can risk patients' health by restricting access to needed treatments," said Karl Uhlendorf, vice president of Pharmaceutical Research and Manufacturers of America, in a statement. Spending on specialty drugs grew by 17 percent last year — and similar increases will occur for the foreseeable future, says Richard Faris, a vice president at Medco. Spending on specialty drugs can account for 15 percent to 25 percent of an employer’s total pharmacy benefit costs, he said. Seeing a gain It’s not just drugmakers who benefit from the specialty-drug business. Firms such as Medco often run their own specialty pharmacies, which oversee all aspects of specialty drugs, from purchasing to making sure patients take them correctly. The specialty pharmacy business brought in $11.3 billion for Medco last year, or 17 percent of its overall revenue. Because so many new specialty drugs are expected on the market soon — and a growing number of employers are likely to want additional oversight — Medco projects that its specialty pharmacy could represent 40 percent of the firm’s entire revenue by 2020. Surveys by benefit management firms, such as Mercer, show many employers try other methods to slow spending on specialty drugs, rather than tiers. Those other steps include requiring patients to try less costly drugs first, or steering patients to designated pharmacies where they’ve negotiated discounts. Employers sometimes balk at the tiers because they fear that patients might stop using the drugs or will complain to human resource departments about the cost. Some recent studies seem to bear out the utilization concern: Ten percent of patients failed to fill their initial prescription for oral cancer drugs from 2007 to 2009, according to a survey of claims for cancer patients done by Avalere. Patients who owed more than $500 at the pharmacy counter were four times more likely to not fill their prescriptions than those who owed $100 or less. The study looked at people with both employer-based insurance and those on Medicare. The study alarmed some patient advocates. "More and more cancer drugs are on those lists, and the cost to cancer patients is going to grow accordingly," says Stephen Finan of the American Cancer Society Cancer Action Network. His group and others want limits on how much patients have to pay toward their drugs. Because no one yet knows what the federal government will require in the essential benefits that must be offered by insurers in 2014, the groups are turning their lobbying to state legislatures, where more than a dozen considered measures aimed at regulating specialty drug payments by patients. New York has essentially barred insurers from charging patients a percentage of the drug’s cost. Delaware lawmakers put in place a one-year ban on the practice while it is studied further. Meanwhile, proposals to bar or restrict specialty tiers have been introduced in California, Maryland, South Carolina, Massachusetts and several other states. None has passed. A struggle continues After calling a patient advocacy group in search of financial help, Ariba was referred to a pharmacy program that said it would pick up her entire share of the cost of the drugs. Before she could fill her first prescription, the program informed her that her insurer had given them incorrect information and that she would actually have to pay $400 a month toward the medication she must take from now until April. Ariba, who says she lives on about $1,200 a month in Social Security disability payments and some savings, is devastated. She already pays more than $600 a month to keep her insurance under a plan offered by her former employer, having quit her job in September while undergoing five-day-a-week chemotherapy. "I’ll probably have to go that route and pay the $400," she says. "I have a little money put aside, but it will wipe me out. It’s very frustrating. I have resorted to begging people, saying 'Can you help me?'" - Provided by Kaiser Health News. Republish Email Facebook Digg Twitter Share [ Close ] When publishing articles from AHN we require that you follow several simple rules and that you abide by our Terms and Conditions. You may: Use and display the provided article text on a website or blog. Under the following conditions: You may not republish the article(s) wholesale, automatically or systematically; articles must be republished individually. You may not sell license or redistribute the content without specific permission. Email us if you’d like to. You must display and attribute the article in the manner specified by AHN (but not in any way that suggests that we endorse you or your use of the work). You may not remove ads, logos or tracking information from the article. You may display the article on a website, but you may not use the article for any other commercial purposes. You may not alter, rewrite, transform, or build upon the article. You may only use provided the javascript code to request the article from our systems. Copy and paste the following into your blog entry or the HTML on your page. It will automatically deliver the article as the page loads. <script type="text/javascript" src="http://www.allheadlinenews.com//syndicator?storyid=7020884860"></script> << Return to script page License THE WORK (AS DEFINED BELOW) IS PROVIDED UNDER THE TERMS OF THIS LICENSE ("LICENSE"). THE WORK IS PROTECTED BY COPYRIGHT AND/OR OTHER APPLICABLE LAW. ANY USE OF THE WORK OTHER THAN AS AUTHORIZED UNDER THIS LICENSE OR COPYRIGHT LAW IS PROHIBITED. BY EXERCISING ANY RIGHTS TO THE WORK PROVIDED HERE, YOU ACCEPT AND AGREE TO BE BOUND BY THE TERMS OF THIS LICENSE. TO THE EXTENT THIS LICENSE MAY BE CONSIDERED TO BE A CONTRACT, THE LICENSOR GRANTS YOU THE RIGHTS CONTAINED HERE IN CONSIDERATION OF YOUR ACCEPTANCE OF SUCH TERMS AND CONDITIONS. 1. Definitions "Collective Work" means a work, such as a periodical issue, anthology or encyclopedia, in which the Work in its entirety in unmodified form, along with one or more other contributions, constituting separate and independent works in themselves, are assembled into a collective whole. A work that constitutes a Collective Work will not be considered a Derivative Work (as defined below) for the purposes of this License. "Derivative Work" means a work based upon the Work or upon the Work and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Work may be recast, transformed, or adapted, except that a work that constitutes a Collective Work will not be considered a Derivative Work for the purpose of this License. For the avoidance of doubt, where the Work is a musical composition or sound recording, the synchronization of the Work in timed-relation with a moving image ("synching") will be considered a Derivative Work for the purpose of this License. "Licensor" means the individual, individuals, entity or entities that offers the Work under the terms of this License. "Original Author" means the individual, individuals, entity or entities who created the Work. "Work" means the copyrightable work of authorship offered under the terms of this License. "You" means an individual or entity exercising rights under this License who has not previously violated the terms of this License with respect to the Work, or who has received express permission from the Licensor to exercise rights under this License despite a previous violation. 2. Fair Use Rights. Nothing in this license is intended to reduce, limit, or restrict any rights arising from fair use, first sale or other limitations on the exclusive rights of the copyright owner under copyright law or other applicable laws. 3. License Grant. Subject to the terms and conditions of this License, Licensor hereby grants You a worldwide, non-exclusive, revocable (for the duration of the applicable copyright) license to exercise the rights in the Work as stated below: to reproduce the Work, to incorporate the Work into one or more Collective Works; The above rights may be exercised on freely and openly accessible web media formats . The above rights include the right to make such modifications as are technically necessary to exercise the rights in other media and formats, but otherwise you have no rights to make any alterations or Derivative Works. All rights not expressly granted by Licensor are hereby reserved, including but not limited to the rights set forth in Sections 4(d) and 4(e). 4. Restrictions.The license granted in Section 3 above is expressly made subject to and limited by the following restrictions: You may publicly display the Work only under the terms of this License, and You must include a copy of, or the Uniform Resource Identifier for, this License with every copy of the Work You publicly display. You may not offer or impose any terms on the Work that restrict the terms of this License or the ability of a recipient of the Work to exercise the rights granted to that recipient under the terms of the License. You may not sublicense the Work. You must keep intact all notices that refer to this License and to the disclaimer of warranties. When You publicly display the Work, You may not impose any technological measures on the Work that restrict the ability of a recipient of the Work from You to exercise the rights granted to that recipient under the terms of the License. This Section 4(a) applies to the Work as incorporated in a Collective Work, but this does not require the Collective Work apart from the Work itself to be made subject to the terms of this License. If You create a Collective Work, upon notice from any Licensor You must, to the extent practicable, remove from the Collective Work any credit as required by Section 4(c), as demanded. You may not exercise any of the rights granted to You in Section 3 above in any manner that is primarily intended for or directed toward commercial advantage or private monetary compensation. The exchange of the Work for other copyrighted works by means of digital file-sharing or otherwise shall not be considered to be intended for or directed toward commercial advantage or private monetary compensation, provided there is no payment of any monetary compensation in connection with the exchange of copyrighted works. If You publicly display the Work (as defined in Section 1 above) or Collective Works (as defined in Section 1 above), You must, unless a request has been made pursuant to Section 4(a), keep intact all copyright notices for the Work and provide, reasonable to the medium or means You are utilizing: (i) the name of the Original Author (or pseudonym, if applicable) if supplied, and/or (ii) if the Original Author and/or Licensor designate another party or parties (e.g. a sponsor institute, publishing entity, journal) for attribution ("Attribution Parties") in Licensor's copyright notice, terms of service or by other reasonable means, the name of such party or parties; the title of the Work if supplied; to the extent reasonably practicable, the Uniform Resource Identifier, if any, that Licensor specifies to be associated with the Work, unless such URI does not refer to the copyright notice or licensing information for the Work. The credit required by this Section 4(c) may be implemented in any reasonable manner; provided, however, that in the case of a Collective Work, at a minimum such credit will appear, if a credit for all contributing authors of the Collective Work appears, then as part of these credits and in a manner at least as prominent as the credits for the other contributing authors. For the avoidance of doubt, You may only use the credit required by this clause for the purpose of attribution in the manner set out above and, by exercising Your rights under this License, You may not implicitly or explicitly assert or imply any connection with, sponsorship or endorsement by the Original Author, Licensor and/or Attribution Parties, as appropriate, of You or Your use of the Work, without the separate, express prior written permission of the Original Author, Licensor and/or Attribution Parties. 5. Representations, Warranties and Disclaimer UNLESS OTHERWISE MUTUALLY AGREED TO BY THE PARTIES IN WRITING, LICENSOR OFFERS THE WORK AS-IS AND ONLY TO THE EXTENT OF ANY RIGHTS HELD IN THE LICENSED WORK BY THE LICENSOR. THE LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE WORK, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF TITLE, MARKETABILITY, MERCHANTIBILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR THE ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE PRESENCE OF ABSENCE OF ERRORS, WHETHER OR NOT DISCOVERABLE. SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OF IMPLIED WARRANTIES, SO SUCH EXCLUSION MAY NOT APPLY TO YOU. 6. Limitation on Liability. EXCEPT TO THE EXTENT REQUIRED BY APPLICABLE LAW, IN NO EVENT WILL LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR EXEMPLARY DAMAGES ARISING OUT OF THIS LICENSE OR THE USE OF THE WORK, EVEN IF LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 7. Termination This License and the rights granted hereunder will terminate automatically upon any breach by You of the terms of this License. Individuals or entities who have received Collective Works (as defined in Section 1 above) from You under this License, however, will not have their licenses terminated provided such individuals or entities remain in full compliance with those licenses. Sections 1, 2, 5, 6, 7, and 8 will survive any termination of this License. Subject to the above terms and conditions, the license granted here is perpetual (for the duration of the applicable copyright in the Work). Notwithstanding the above, Licensor reserves the right to release the Work under different license terms or to stop distributing the Work at any time; provided, however that any such election will not serve to withdraw this License (or any other license that has been, or is required to be, granted under the terms of this License), and this License will continue in full force and effect unless terminated as stated above. 8. Miscellaneous Each time You distribute or publicly digitally perform the Work (as defined in Section 1 above) or a Collective Work (as defined in Section 1 above), the Licensor offers to the recipient a license to the Work on the same terms and conditions as the license granted to You under this License. If any provision of this License is invalid or unenforceable under applicable law, it shall not affect the validity or enforceability of the remainder of the terms of this License, and without further action by the parties to this agreement, such provision shall be reformed to the minimum extent necessary to make such provision valid and enforceable. No term or provision of this License shall be deemed waived and no breach consented to unless such waiver or consent shall be in writing and signed by the party to be charged with such waiver or consent. This License constitutes the entire agreement between the parties with respect to the Work licensed here. There are no understandings, agreements or representations with respect to the Work not specified here. Licensor shall not be bound by any additional provisions that may appear in any communication from You. This License may not be modified without the mutual written agreement of the Licensor and You. There are no third-party beneficiaries to this Licesnse. You waive any right to jury trial in connection with any action or litigation in any way arising out of or related to this License. You agree to pay all reasonable attorney fees and other costs incurred by Your breach of this license. This agreement will be governed and construed in accordance with the laws of the State of Florida without regard to its conflicts of law provisions. You agree to submit to the personal jurisdiction of the state and federal courts located in Palm Beach County in the State of Florida, and any cause of action which arise from use of this web site or from interpretation of these terms and conditions must be filed in the state and federal courts located in Palm Beach County, State of Florida. If any provision of this agreement shall be unlawful, void, or for any reason unenforceable, then that provision shall be deemed severable from this agreement and shall not affect the validity and enforceability of any remaining provisions. Any remaining provisions shall be given effect to the fullest extent possible. Need more news? visit FeedSyndicate for all of your content needs This is a BETA service and subject to change or cancellation. Recent Posts Most Popular Comments Recent Comments Popular Threads Advertisement Advertisement [ CLOSE ] --> [ CLOSE ] [ CLOSE ] [ CLOSE ] Submit News | Privacy Policy | Terms of Use | Contact Us | News and Content Feeds | Journalism Jobs Follow AHN on Twitter AHN Social News connects you with friends and the news © 2011 AHN All Rights Reserved | Hosted on the NewsBahn™

Other News on Tuesday, 23 August 2011
Fight for Gaddafi compound will be hard: rebels |
Analysis: After Libya, eyes turn to Syrian revolt |
Muslim rebels in Philippines offered wider autonomy at start of peace talks
Ford, Toyota team up on hybrid systems for trucks and SUVs
Yemen politician dies of wounds from attack on Saleh |
HP unveils new desktop, vows continued PC support
Justin Bieber releases "Director's Fan Cut" of "Never Say Never" exclusively to Target
Russian mayor killed after alleging corruption |
Gaza militants to stop rocket attacks, Israel holds large-scale offensive
Jimmy Fallon to return to 'SNL' as host in December
PGA Tour's FedEx Cup playoffs: what are they really?
Irene to become a Category 3 storm as it approaches Florida coast
Trinidad declares state of emergency to fight crime |
Wing walker plummets to his death at Michigan air show
Most online consumers only clicks away from digital disaster
Ukraine says thwarts holiday terrorist bomb |
S&P upgrades Google stock days after sell view |
HP unveils new PC days after saying it exits unit |
Skype confirms pact to buy GroupMe |
Analysis: Google/Motorola could be peak of patent price spike |
Some of WikiLeaks' Bank of America data destroyed |
Groupon's Mason to tie the knot right after planned IPO |
Ghost musical to appear on Broadway |
Lil Wayne sets Tha Carter IV release after VMAs |
U2 singer Bono denies reports of health scare |
Reality star Kim Kardashian weds Kris Humphries |
Son rallies loyalists for Gaddafi's Tripoli fightback |
Paleteria La Super Issues Allergy Alert on Undeclared Walnuts, Milk and Coconut in Their Nut, Esquimal , and Pina Colada Ice Cream Popsicles
China urges Libya to protect investments |
Raiders take ex-Ohio State quarterback Terrelle Pryor in supplemental draft
Japan PM on way out, leadership race wide open |
Three refugees killed as Somali troops said to hijack food aid
The Ultimate Fighter goes lighter: Season 14's Featherweight, Bantamweight casts revealed
Denise Richards turns down Two and a Half Men guest spot
Readers Face Multiple Dilemmas About Insurance Coverage, Costs
"The Glee Project" announces winners
Workers Squeezed As Employers Pass Along High Costs Of Specialty Drugs
Kim Kardashian's Wedding Band Performs Pitbull song in front of Lindsay Lohan
Josh Tomlin, Indian starters keeping Tribe in thick of sizzling pennant race
Costa Rica nabs man sought on Texas child abuse charge |
U.S. concerned about Vietnam detention of protesters |
India PM calls all-party meet on anti-graft protests |
Irene strengthens to Category 2 hurricane |
Seoul must change to trustpolitik with North, says Park |
Syrian forces shoot three during U.N. visit: activists |
U.N. says 600 die in South Sudan clashes |
Microsoft partners with China firm on cloud-computing |
MP3tunes wins end to part of EMI copyright case |
Redemption clock for eHarmony is ticking |
Malware targeting Android devices jumped in Q2: McAfee |
Jackson fans say tribute concert doomed to fai' |
David Letterman jokes about militant death threat |
Hound Dog songwriter Jerry Leiber dies at 78 |
Songwriter Nickolas Ashford dies at age 70 |
Blast at Russian ammunition depot kills six |
Gaddafi son affair surmountable blow for rebels |
Researchers report breakthrough in ALS cause
U.N. nuclear watchdog visits Iran sites: report |
Study: Marriage boosts survival after heart surgery
Will Smith, Jada Pinkett Smith reportedly separating
2011 the year of billion-dollar disasters
UN rights body urges Syria to halt military crackdown
China rail firm boss, blamed for crash, dies of heart attack |
Libyan colonel discloses Gaddafi's Tunisian attack plot
Special report: In Libya, the cellphone as weapon |
Delinquent debt on the rise for the largest and smallest companies
Greece forecasts economic contraction to be worse than expected
Rebels control most of Tripoli, Gaddafi in Libya: U.S. |
Injuries are Giant concern as season approaches
Browns lock up All-Pro tackle Joe Thomas with seven year extension
Afghanistan fights population growth with birth control |
Invisible millions pay price of statelessness |
Exclusive: Apple suppliers building cheaper, 8GB iPhone |
China Telecom says still in talks with Apple on iPhone |
Nintendo jumps on talk of 3DS add-on, revamp |
Universal Display to license OLED technology to Samsung unit |
Special report: In Libya, the cellphone as weapon |
No illegal drugs in Winehouse toxicology report |
Paul Rudd is nobody's Idiot Brother |
Mad Men inspires look back for new TV hits |
George Michael returns to stage, announces split |
Jackson fans say tribute concert doomed to fail |
Greece at new risk of being pushed off euro
Bodies of missing Tenn. mom, Jo Ann Bain, and daughter found
Female Breasts Are Bigger Than Ever
AMD Trinity Accelerated Processing Units Now in Volume Production
The Avengers (2012 film), made the second biggest opening- and single-day gross of all-time
AMD to Start Production of piledriver
Ivy Bridge Quad-Core, Four-Thread Desktop CPUs
Islamists Protest Lady Gaga's Concert in Indonesia
Japan Successfully Broadcasts an 8K Signal Over the Air
ECB boosts loans to 1 trillion Euro to stop credit crunch
Egypt : Mohammed Morsi won with 52 percent
What do you call 100,000 Frenchmen with their hands up
AMD Launches AMD Embedded R-Series APU Platform
Fed Should not Ignore Emerging Market Crisis
Fed casts shadow over India, emerging markets
Why are Chinese tourists so rude? A few insights

USD EUR - 1 year graph		BlogMeter 1.01